Promoter Methylation and Expression Status of Cytotoxic T-Lymphocyte-Associated Antigen-۴ Gene in Patients with Lupus
محل انتشار: فصلنامه اپیژنتیک، دوره: 2، شماره: 1
سال انتشار: 1400
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 127
فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_JEPUSB-2-1_005
تاریخ نمایه سازی: 12 تیر 1401
چکیده مقاله:
Objectives: Systemic lupus erythematous (SLE) is an autoimmune disease with both genetic susceptibility and epigenetic modifications. Autoantibodies directly contribute to the destruction of some organs such as kidneys, joints, skin, lungs, central nervous system, and blood-forming (hematopoietic) system. The CTLA۴ plays an important role in inhibition of the activity of T cells and preventing autoimmune disorders, for example; the lupus. We analyzed the promoter methylation, polymorphism, and expression status in CTLA۴ gene in patients with lupus. Methods: Genomic DNA was isolated from ۵۰ individuals’ blood samples with SLE and ۵۰ control participants. CTLA۴ gene polymorphisms analysis in polymorphic site, -۳۱۸(CT) and +۴۹(AG), was done by Tetra-ARMS-PCR. Methylation-specific polymerase chain reaction (MS-PCR) was used to estimate promoter hyper methylation of the CTLA۴ gene. The present paper also analyzed CTLA۴ mRNA levels in ۳۰ blood samples from the intended participants, and healthy control by real-time PCR. Results: Changes in promoter methylation of CTLA۴ gene were remarkably different in patients with lupus than healthy controls (OR= ۰.۴۸; ۹۵% CI= ۰.۱۹۵۹, ۱.۲۰۲; P-value= ۰.۰۰۵). However, gene expression level of CTLA۴ was not statistically different in patients than the healthy control group. Conclusions: This epigenetic study gives us an overview of the role of CTLA۴ promoter methylation in pathogenesis of SLE, which cause preventing its expression. As we know CTLA۴ has the role in immune regulation and downregulates immune responses. In the future a comprehensive understanding of the epigenetic mechanisms contributing to SLE will likely enable development of new therapeutic agents and strategies that target the dysregulated genes or correct the aberrant epigenetic modifications (Epigenetic therapies for SLE).
کلیدواژه ها:
نویسندگان
Shahin Nosrat zehi
Department of internal medicine, Zahean university of medical science, Zahedan, Iran
Mahin Nosrat zehi
Department of internal medicine, Zahean university of medical science, Zahedan, Iran
Sahar Atighi
Department of Biology, University of Sistan and Baluchestan, Zahedan, Iran
Tahereh Dianat
Department of Biology, University of Sistan and Baluchestan, Zahedan, Iran
Khadije Kord Tamandani
Department of internal medicine, Zahean university of medical science, Zahedan, Iran
مراجع و منابع این مقاله:
لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :